Are antiangiogenics a good ‘partner’ for immunotherapy in ovarian cancer?

Ovarian cancer (OC) is associated with poor survival because there are a limited number of effective therapies. Two processes key to OC progression, angiogenesis and immune evasion, act synergistically to promote tumor progression. Tumor-associated angiogenesis promotes immune evasion, and tumor-rel...

Descripción completa

Detalles Bibliográficos
Autores principales: García-Martínez, Elena, Redondo, Andres, Piulats, Josep Maria, Rodríguez, Analía, Casado, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2020
Materias:
Review Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7524856/
https://www.ncbi.nlm.nih.gov/pubmed/32691290
http://dx.doi.org/10.1007/s10456-020-09734-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7524856/
https://www.ncbi.nlm.nih.gov/pubmed/32691290
http://dx.doi.org/10.1007/s10456-020-09734-w

Ejemplares similares